<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. )*
VIMRX PHARMACEUTICALS INC.
---------------------------------------------
(Name of Issuer)
Common Stock, $0.001 par value per share
---------------------------------------------
(Title of Class of Securities)
927186 10 6
---------------------------------------------
(CUSIP Number)
December 17, 1997
---------------------------------------------
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this
Schedule is filed.
[ ] Rule 13d-1(b)
[x] Rule 13d-1(c)
[ ] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
(Continued on following page(s))
Page 1 of 6 Pages
<PAGE>
CUSIP No. 927186 10 6 13G Page 2 of 6 Pages
- ------------------------------------------------------------------------------
(1) Names of Reporting Persons. I.R.S. Identification Nos. of Above Persons
(entities only)
BAXTER HEALTHCARE CORPORATION
I.R.S. Identification Number: 36-2999006
BAXTER INTERNATIONAL INC.
I.R.S. Identification Number: 36-0781620
- ------------------------------------------------------------------------------
(2) Check the Appropriate Box if a Member of a Group (See Instructions)
(a) [ ]
(b) [ ]
- ------------------------------------------------------------------------------
(3) SEC Use Only
- ------------------------------------------------------------------------------
(4) Citizenship or Place of Organization
Delaware
- ------------------------------------------------------------------------------
Number of Shares (5) Sole Voting Power
Beneficially Owned -0-
by Each Reporting -------------------------------------------
Person With (6) Shared Voting Power
11,000,000
-------------------------------------------
(7) Sole Dispositive Power
-0-
-------------------------------------------
(8) Shared Dispositive Power
11,000,000
- ----------------------------------------------------------------------------
(9) Aggregate Amount Beneficially Owned by Each Reporting Person
11,000,000
----------------------------------------------------------------------------
(10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
Instructions)
[ ]
- ----------------------------------------------------------------------------
(11) Percent of Class Represented by Amount in Row (9)
16.4%
- ----------------------------------------------------------------------------
(12) Type of Reporting Person (See Instructions)
CO
- ----------------------------------------------------------------------------
<PAGE>
CUSIP No. 927186 10 6 13G Page 3 of 6 Pages
This Schedule 13G relates to the holdings of Baxter Healthcare Corporation, a
Delaware corporation ("Purchaser"), of 11,000,000 shares (the "Shares") of
common stock, $0.001 par value per share, of VIMRX Pharmaceuticals, Inc., a
Delaware corporation. This Schedule does not report any change in beneficial
ownership and is filed only to report that Purchaser holds the Shares as a
passive investor pursuant to Rule 13d-1(c).
Item 1(a). Name Of Issuer:
VIMRX Pharmaceuticals, Inc.
Item 1(b). Address of Issuer's Principal Executive Offices:
2571 Centerville Road
Suite 210
Wilmington, Delaware 19808
Item 2(a). Name of Person Filing:
This statement is being filed by Purchaser and Baxter International Inc., a
Delaware corporation and the owner of 100% of the capital stock of
Purchaser ("Parent").
Item 2(b). Address of Principal Business Office or, if none, Residence:
One Baxter Parkway
Deerfield, Illinois 60015
Item 2(c). Citizenship:
Delaware
Item 2(d). Title of Class of Securities:
Common stock, $0.001 par value per share, of VIMRX Pharmaceuticals, Inc.
Item 2(e). CUSIP Number:
927186 10 6
<PAGE>
CUSIP No. 927186 10 6 13G Page 4 of 6 Pages
Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or
(c), check whether filing person is a:
(a) [ ] Broker or dealer registered under Section 15 of the Act
(b) [ ] Bank as defined in Section 3(a)(6) of the Act
(c) [ ] Insurance company as defined in Section 3(a)(19) of the Act
(d) [ ] Investment company registered under Section 8 of the
Investment Company Act
(e) [ ] An investment adviser in accordance with Rule 13d-
1(b)(1)(ii)(E)
(f) [ ] An employee benefit plan or endowment fund in accordance with
Rule 13d-1(b)(1)(ii)(F)
(g) [ ] A parent holding company or control person in accordance with
Rule 13d-1(b)(ii)(G)
(h) [ ] A savings association as defined in Section 3(b) of the
Federal Deposit Insurance Act (12 U.S.C.1813)
(i) [ ] A church plan that is excluded from the definition of an
investment company under Section 3(c)(14) of the Investment
Company Act of 1940 (15 U.S.C. 80a-3)
(j) [ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(J)
If this statement is filed pursuant to Rule 13d-1(c), check this box.
[x]
Item 4. Ownership
This Schedule does not report any change in beneficial ownership and is
filed only to report that Purchaser holds the Shares as a passive
investor pursuant to Rule 13d-1(c).
(a) Amount Beneficially Owned:
11,000,000
(b) Percent of Class:
16.4%
(c) Number of shares as to which the person has:
(i) sole power to vote or direct the vote: -0-
(ii) shared power to vote or direct the vote: 11,000,000
(iii) sole power to dispose or to direct the disposition of: -0-
<PAGE>
CUSIP No. 927186 10 6 13G Page 5 of 6 Pages
(iv) shared power to dispose or to direct the disposition of:
11,000,000
Item 5. Ownership of Five Percent or Less of a Class.
If this Schedule is being filed to report the fact that as of the date
hereof the reporting person has ceased to be the beneficial owner of
more than five percent on the class of securities, check the following
box. [ ]
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
Not applicable.
Item 7. Identification and Classification of the Subsidiary Which Acquired the
Security Being Reported on by the Parent Holding Company.
Not applicable.
Item 8. Identification and Classification of Members of the Group.
Not applicable.
Item 9. Notice of Dissolution of Group.
Not applicable.
Item 10. Certification.
By signing below, each of Purchaser and Parent certifies that, to the
best of their knowledge and belief, the securities referred to above
were not acquired and are not held for the purpose of or with the
effect of changing or influencing the control of the issuer of the
securities and were not acquired and are not held in connection with or
as a participant in any transaction having that purpose or effect.
<PAGE>
CUSIP No. 927186 10 6 13G Page 6 of 6 Pages
Signature.
After reasonable inquiry and to the best of their knowledge and belief,
each of Purchaser and Parent certifies that the information set forth in this
statement is true, complete and correct.
Date: September 15, 1998
BAXTER HEALTHCARE CORPORATION
By: /s/ Jan Stern Reed
-----------------------
Corporate Secretary
BAXTER INTERNATIONAL INC.
By: /s/ Jan Stern Reed
-----------------------
Corporate Secretary
